{"nctId":"NCT01743027","briefTitle":"Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis","startDateStruct":{"date":"2013-01"},"conditions":["Allergic Conjunctivitis"],"count":902,"armGroups":[{"label":"AL-4943A","type":"EXPERIMENTAL","interventionNames":["Drug: AL-4943A ophthalmic solution"]},{"label":"PATADAY","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olopatadine hydrochloride ophthalmic solution, 0.2%"]},{"label":"PATANOL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olopatadine hydrochloride ophthalmic solution, 0.1%"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AL-4943A ophthalmic solution vehicle"]}],"interventions":[{"name":"AL-4943A ophthalmic solution","otherNames":[]},{"name":"Olopatadine hydrochloride ophthalmic solution, 0.2%","otherNames":["PATADAY®"]},{"name":"Olopatadine hydrochloride ophthalmic solution, 0.1%","otherNames":["PATANOL®"]},{"name":"AL-4943A ophthalmic solution vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able to be dosed in both eyes, able and willing to make the required study visits and to follow instructions.\n* Negative urine pregnancy test if female of childbearing potential and use adequate birth control throughout the study period.\n* Diagnostic skin test indicative of allergy for cat hair, cat dander, grasses, ragweed, dust mite, dog dander, cockroach and/or trees within 24 months prior to Visit 1 or at Visit 1.\n* History of seasonal or perennial allergic conjunctivitis for at least 1 year prior to Visit 1.\n* Best-corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method).\n* Manifest a positive bilateral Conjunctival Allergen Challenge (CAC) test response.\n* Willing to discontinue contact lens wear for at least 72 hours prior to Visit 1 and throughout the study.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Known history or presence of persistent dry eye syndrome, or currently requires frequent use of artificial tears, gels or lubricants, presence of punctal plugs, use of Restasis®, or topical ocular corticosteroids for dryness of eyes.\n* Presence of an ocular condition that may affect the study outcomes.\n* History or evidence of ocular surgery (including refractive procedures such as LASIK, PRK and RK) within 6 months of Visit 1.\n* Presence of signs/symptoms of active allergic conjunctivitis at the start of Visits 1, 2, 3A, or 4.\n* History of anaphylactic reaction to any allergens used in this study.\n* Current evidence or recent (within 6 months) history of severe, unstable, or uncontrolled medical conditions and/or other relevant systemic diseases.\n* Use of any disallowed medication without protocol-specified washout period prior to Visit 1, or during the study.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Ocular Itching at Onset of Action","description":"A treatment efficacy CAC was performed 27 minutes after drop installation. Ocular itching was assessed by the participant on a 0-4 scale (0= none, 4 = incapacitating itch). Average of ocular itching score over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.069"},{"groupId":"OG001","value":"0.47","spread":"0.069"},{"groupId":"OG002","value":"0.59","spread":"0.070"},{"groupId":"OG003","value":"1.91","spread":"0.095"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.075"},{"groupId":"OG001","value":"0.61","spread":"0.075"},{"groupId":"OG002","value":"0.79","spread":"0.076"},{"groupId":"OG003","value":"1.99","spread":"0.103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.081"},{"groupId":"OG001","value":"0.61","spread":"0.082"},{"groupId":"OG002","value":"0.83","spread":"0.083"},{"groupId":"OG003","value":"1.82","spread":"0.113"}]}]}]},{"type":"PRIMARY","title":"Mean Ocular Itching at 24 Hours Duration of Action","description":"A treatment efficacy CAC was performed 24 hours after drop instillation on Day 0. Ocular itching was assessed by the participant on a 0-4 scale (0= none, 4 = incapacitating itch). Average of ocular itching score over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.093"},{"groupId":"OG001","value":"1.33","spread":"0.093"},{"groupId":"OG002","value":"1.53","spread":"0.093"},{"groupId":"OG003","value":"2.30","spread":"0.132"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.092"},{"groupId":"OG001","value":"1.48","spread":"0.092"},{"groupId":"OG002","value":"1.70","spread":"0.091"},{"groupId":"OG003","value":"2.37","spread":"0.130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.097"},{"groupId":"OG001","value":"1.41","spread":"0.097"},{"groupId":"OG002","value":"1.64","spread":"0.096"},{"groupId":"OG003","value":"2.14","spread":"0.137"}]}]}]},{"type":"SECONDARY","title":"Mean Conjunctival Redness at Onset of Action","description":"A treatment efficacy CAC was performed 27 minutes after drop installation. Conjunctival redness was assessed by the investigator on a 0-4 scale (0=none, 4=extremely severe). Average of conjunctival redness score over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.082"},{"groupId":"OG001","value":"1.62","spread":"0.082"},{"groupId":"OG002","value":"1.65","spread":"0.083"},{"groupId":"OG003","value":"1.96","spread":"0.113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"0.082"},{"groupId":"OG001","value":"1.96","spread":"0.082"},{"groupId":"OG002","value":"1.97","spread":"0.083"},{"groupId":"OG003","value":"2.10","spread":"0.112"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"0.082"},{"groupId":"OG001","value":"1.97","spread":"0.082"},{"groupId":"OG002","value":"1.97","spread":"0.083"},{"groupId":"OG003","value":"2.15","spread":"0.113"}]}]}]},{"type":"SECONDARY","title":"Mean Conjunctival Redness at 24 Hours Duration of Action","description":"A treatment efficacy CAC was performed 24 hours after drop instillation on Day 0. Conjunctival redness was assessed by the investigator on a 0-4 scale (0=none, 4=extremely severe). Average of conjunctival redness score over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"0.074"},{"groupId":"OG001","value":"2.01","spread":"0.073"},{"groupId":"OG002","value":"1.97","spread":"0.073"},{"groupId":"OG003","value":"2.09","spread":"0.104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.04","spread":"0.073"},{"groupId":"OG001","value":"2.21","spread":"0.073"},{"groupId":"OG002","value":"2.10","spread":"0.073"},{"groupId":"OG003","value":"2.22","spread":"0.104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"0.078"},{"groupId":"OG001","value":"2.19","spread":"0.078"},{"groupId":"OG002","value":"2.07","spread":"0.077"},{"groupId":"OG003","value":"2.23","spread":"0.110"}]}]}]},{"type":"SECONDARY","title":"Mean Total Redness at Onset of Action","description":"A treatment efficacy CAC was performed 27 minutes after drop installation. Conjunctival redness, ciliary redness, and episcleral redness were assessed by the investigator on 0-4 scale (0=none, 4=extremely severe). Total redness is a composite variable summing conjunctival redness, ciliary redness, and episcleral redness scores (resultant score 0-12). The average of total redness over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":"0.239"},{"groupId":"OG001","value":"4.73","spread":"0.240"},{"groupId":"OG002","value":"4.82","spread":"0.243"},{"groupId":"OG003","value":"5.93","spread":"0.330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":"0.240"},{"groupId":"OG001","value":"5.73","spread":"0.240"},{"groupId":"OG002","value":"5.85","spread":"0.243"},{"groupId":"OG003","value":"6.50","spread":"0.330"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":"0.244"},{"groupId":"OG001","value":"5.88","spread":"0.245"},{"groupId":"OG002","value":"5.88","spread":"0.248"},{"groupId":"OG003","value":"6.67","spread":"0.337"}]}]}]},{"type":"SECONDARY","title":"Mean Total Redness at 24 Hours Duration of Action","description":"A treatment efficacy CAC was performed 24 hours after drop instillation on Day 0. Conjunctival redness, ciliary redness, and episcleral redness were assessed by the investigator on 0-4 scale (0=none, 4=extremely severe). Total redness is a composite variable summing conjunctival redness, ciliary redness, and episcleral redness scores (resultant score 0-12). The average of total redness over both eyes was analyzed.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.39","spread":"0.214"},{"groupId":"OG001","value":"5.77","spread":"0.213"},{"groupId":"OG002","value":"5.66","spread":"0.212"},{"groupId":"OG003","value":"6.12","spread":"0.302"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.87","spread":"0.216"},{"groupId":"OG001","value":"6.42","spread":"0.215"},{"groupId":"OG002","value":"6.11","spread":"0.215"},{"groupId":"OG003","value":"6.49","spread":"0.306"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","spread":"0.230"},{"groupId":"OG001","value":"6.41","spread":"0.228"},{"groupId":"OG002","value":"6.02","spread":"0.228"},{"groupId":"OG003","value":"6.49","spread":"0.325"}]}]}]},{"type":"SECONDARY","title":"Proportion of Ocular Itching Responders at Onset of Action","description":"A treatment efficacy CAC was performed 27 minutes after drop installation. Ocular itching was assessed by the participant on a 0-4 scale (0= none, 4 = incapacitating itch). A responder was defined as a participant with zero-itch (a score of zero on ocular itching for both eyes) or with at least 2 units reduction in ocular itching relative to the baseline confirmatory CAC score. Ocular itching score was averaged across both eyes and over the 3 post-CAC assessments (3, 5, and 7 minutes) for the calculation of units reduction. Proportion of Ocular Itching Responders is reported as a percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"73.7","spread":null},{"groupId":"OG002","value":"59.6","spread":null},{"groupId":"OG003","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Itch Responders at 24 Hours Duration of Action","description":"A treatment efficacy CAC was performed 24 hours after drop instillation on Day 0. Ocular itching was assessed by the participant on a 0-4 scale (0= none, 4 = incapacitating itch). A responder was defined as a participant with zero-itch (a score of zero on ocular itching for both eyes) or with at least 2 units reduction in ocular itching relative to the baseline confirmatory CAC score. Ocular itching score was averaged across both eyes and over the 3 post-CAC assessments (3, 5, and 7 minutes) for the calculation of units reduction. Proportion of Ocular Itching Responders is reported as a percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"30.3","spread":null},{"groupId":"OG002","value":"26.3","spread":null},{"groupId":"OG003","value":"4.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":98},"commonTop":[]}}}